ब्रेक्सपिप्राज़ोल के इंटरैक्शन

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (अल्प्राज़ोलम लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (एज़ेलास्टिन और फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

…phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with ritonavir), pimozide Benzodiazepines Orally administered midazolam a , triazolam Ergot Derivatives Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (एटाज़ानाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…the description of tardive dyskinesia and its clinical detection, please refer to the sections on Information for Patients and ADVERSE REACTIONS . ) Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs and with amoxapine. (एमोक्सापिन लेबल, चेतावनियां)

Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (एस्ज़ोपिक्लोन लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (एस्टाज़ोलम लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (ऑक्साज़ेपाम लेबल, चेतावनियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ओलिसेरिडिन लेबल, बॉक्स्ड चेतावनी)

Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (कार्बामाज़ेपिन लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (कार्बिनोक्सामिन लेबल, चेतावनियां और सावधानियां)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (कीटोकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (केटामिन लेबल, दवाओं के इंटरैक्शन)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (कोडीन लेबल, बॉक्स्ड चेतावनी)

Colchicine (in patients with normal renal and hepatic function) Use With Caution Antipsychotics: Pimozide Contraindicated Pimozide: [See Contraindications ( 4.2 )] Quetiapine Lurasidone Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. (क्लैरिथ्रोमाइसिन लेबल, दवाओं के इंटरैक्शन)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोनाज़ेपाम लेबल, चेतावनियां)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (क्लोनिडिन लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोबाज़ाम लेबल, चेतावनियां और सावधानियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, चेतावनियां)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (क्लोराज़ेपेट लेबल, चेतावनियां)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (गैबापेंटिन लेबल, चेतावनियां और सावधानियां)

As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking ziprasidone at recommended doses. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (ज़ेलेप्लॉन लेबल, चेतावनियां)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (ज़ोल्पिडेम लेबल, चेतावनियां और सावधानियां)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission [see Drug Interactions (7.6) ]. (टेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (टेपेंटाडोल लेबल, बॉक्स्ड चेतावनी)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (टेमाज़ेपाम लेबल, चेतावनियां)

Avoid trimethobenzamide hydrochloride capsules in patients receiving other drugs that are likely to cause EPS (e.g. antipsychotics) [see Drug Interactions (7.2) ] . (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (ट्रायज़ोलम लेबल, चेतावनियां और सावधानियां)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (डायज़ेपाम लेबल, चेतावनियां)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (डारुनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product: St. (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (डॉक्सीलामिन और पाइरिडोक्सिन लेबल, चेतावनियां और सावधानियां)

Neuroleptic Malignant Syndrome (NMS) A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (ड्यूटेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

…Clinical Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone… (ड्रोनेडेरोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…proarrhythmic effects, thioridazine should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see WARNINGS , CONTRAINDICATIONS… (थायोरिडाज़िन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (नालबुफिन लेबल, बॉक्स्ड चेतावनी)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

Neuropsychiatric agents suvorexant ↑ suvorexant Avoid concomitant use of suvorexant with PAXLOVID. aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, pimavanserin ↑ aripiprazole ↑ brexpiprazole ↑ cariprazine ↑ iloperidone ↑ lumateperone ↑ pimavanserin Dosage adjustment of aripiprazole, brexpiprazole, cariprazine, iloperidone, lumateperone, and… (निर्माट्रेल्विर और रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (पेंटाज़ोसिन और नालोक्सोन लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (प्रीगैबलिन लेबल, चेतावनियां और सावधानियां)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

• Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CNS depressants: Closely monitor for sedation and respiratory depression. (फेनोबार्बिटोन लेबल, दवाओं के इंटरैक्शन)

…coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine GI motility agent: Cisapride Herbal product: St. (फोसएम्प्रेनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (बेलाडोना और ओपियम लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूटॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ब्यूप्रेनॉर्फिन लेबल, बॉक्स्ड चेतावनी)

The concomitant use of CYCLOSET and dopamine receptor antagonists, including neuroleptic drugs, is not recommended. (ब्रोमोक्रिप्टिन लेबल, चेतावनियां और सावधानियां)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (मिडाज़ोलम लेबल, बॉक्स्ड चेतावनी)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (मेटाक्सालोन लेबल, चेतावनियां और सावधानियां)

• Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease. (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (मेथाडोन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (मॉर्फिन लेबल, बॉक्स्ड चेतावनी)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (रिटोनाविर लेबल, बॉक्स्ड चेतावनी)

…Concomitant use of clopidogrel and rifampin should be discouraged Increase active metabolite exposure and risk of bleeding Ticagrelor Prevention or Management: Avoid use Decrease exposure Antipsychotics Haloperidol Decrease plasma concentrations by 70% Lurasidone Prevention or Management: Concomitant use is contraindicated (See CONTRAINDICATIONS ) Decrease exposure Oral… (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

Cerebrovascular Adverse Reactions Including Stroke in Elderly Patients with Dementia-Related Psychosis In placebo-controlled trials in elderly patients with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (रेमिफेंटानिल लेबल, बॉक्स्ड चेतावनी)

Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs. (लुमाटेपेरोन लेबल, चेतावनियां और सावधानियां)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (लेवॉर्फेनॉल लेबल, बॉक्स्ड चेतावनी)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (लोपिनाविर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (लोराज़ेपाम लेबल, चेतावनियां और सावधानियां)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (वाल्बेनाज़िन लेबल, चेतावनियां और सावधानियां)

शराब को नींद लाने वाली दवाओं (ओपिओइड, बेंज़ोडायज़ेपिन, नींद की दवाएं, मसल रिलैक्सेंट) के साथ लेने से खतरनाक स्तर का उनींदापन, धीमी सांस और ओवरडोज़ हो सकता है। (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Based on its structural similarity to TCAs, concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the… (साइक्लोबेंज़ाप्रिन लेबल, दवाओं के इंटरैक्शन)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (सोडियम ऑक्सीबेट लेबल, बॉक्स्ड चेतावनी)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (हाइड्रॉक्सीज़िन लेबल, सावधानियां)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (हाइड्रोमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (इंसुलिन एस्पार्ट लेबल, दवाओं के इंटरैक्शन)

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (इंसुलिन ग्लार्जिन लेबल, दवाओं के इंटरैक्शन)

Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (इंसुलिन डेग्लुडेक लेबल, दवाओं के इंटरैक्शन)

Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (इंसुलिन डेटेमिर लेबल, दवाओं के इंटरैक्शन)

Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (इंसुलिन लिस्प्रो लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects Atypical antipsychotics cause orthostatic hypotension and syncope. (एसेनापिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Hyperpyrexia and Confusion Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reductions or withdrawal of certain antiparkinsonian agents such as levodopa, carbidopa-levodopa, or carbidopa-levodopa extended release. (कार्बिडोपा लेबल, चेतावनियां)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (कार्बिडोपा और लेवोडोपा लेबल, चेतावनियां और सावधानियां)

Withdrawal-Emergent Hyperpyrexia and Confusion Cases of hyperpyrexia and confusion resembling neuroleptic malignant syndrome (NMS) have been reported in association with dose reduction or withdrawal of therapy with carbidopa, levodopa and entacapone. (कार्बिडोपा, लेवोडोपा और एंटाकैपोन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. (कैनाबिडियोल (प्रिस्क्रिप्शन दवा) लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

VRAYLAR and other antipsychotic drugs should be used cautiously in patients at risk for aspiration. (कैरिप्राज़िन लेबल, चेतावनियां और सावधानियां)

• Additive sedative effects when used with other CNS depressants including alcohol (5.1) (कैरिसोप्रोडोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (क्लोरज़ोक्साज़ोन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

SEROQUEL XR and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

The following are examples of medication that may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease… (ग्लिपिज़ाइड लेबल, दवाओं के इंटरैक्शन)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects. (ज़ोनिसामाइड लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

…accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin,… (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Hyperpyrexia and Confusion: In clinical trials, four cases of a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, and altered consciousness), similar to that reported in association with the rapid dose reduction or withdrawal of other dopaminergic drugs, have been reported in association with… (टोलकैपोन लेबल, सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Long-Term Therapy To lessen the likelihood of adverse reactions related to cumulative drug effect, patients with a history of long-term therapy with trifluoperazine hydrochloride and/or other antipsychotics should be evaluated periodically to decide whether the maintenance dosage could be lowered or drug therapy discontinued. (ट्राइफ्लुओपेराज़िन लेबल, सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

…are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Antipsychotics and Antianxiety Agents The concomitant administration of RYANODEX with antipsychotic and antianxiety agents may potentiate their effects on the central nervous system [see Warnings and Precautions ( 5.2 )] . (डैंट्रोलीन लेबल, दवाओं के इंटरैक्शन)

CNS-Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (डैरिडोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Observe patients carefully when the dosage of NORTHERA is changed or when concomitant levodopa is reduced abruptly or discontinued, especially if the patient is receiving neuroleptics. (ड्रॉक्सीडोपा लेबल, चेतावनियां और सावधानियां)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (ड्रोनाबिनोल लेबल, चेतावनियां और सावधानियां)

Since it may be difficult to distinguish neuroleptic malignant syndrome from malignant hyperpyrexia in the perioperative period, prompt treatment with dantrolene should be considered if increases in temperature, heart rate or carbon dioxide production occur. (ड्रोपेरिडोल लेबल, चेतावनियां)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

…medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid… (पियोग्लिटाज़ोन और ग्लिमेपिराइड लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

ERZOFRI and other antipsychotic drugs should be used cautiously in patients at risk for aspiration. (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Hyperpyrexia and Confusion Although not reported with pramipexole in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction,… (प्रैमिपेक्सोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

As with other sedative medications, there is wide interpatient variability in DIPRIVAN dosage requirements, and these requirements may change with time. (प्रोपोफोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (फ्लिबैनसेरिन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning. (फ्लुमाज़ेनिल लेबल, चेतावनियां)

CNS Active Drugs Antipsychotics: See Warnings and Precautions ( 5.2 ) . (फ्लुवोक्सामिन लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (बैक्लोफेन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल और पैरासिटामोल लेबल, दवाओं के इंटरैक्शन)

Other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल, एस्पिरिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (ब्यूटाल्बिटल, पैरासिटामोल और कैफीन लेबल, दवाओं के इंटरैक्शन)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

CNS Depressants and Alcohol Use ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. (मेथोकार्बामोल लेबल, चेतावनियां और सावधानियां)

The CNS-depressant effect of BREVITAL may be additive with that of other CNS depressants, including ethyl alcohol and propylene glycol. (मेथोहेक्सिटल लेबल, चेतावनियां)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (मेप्रोबामेट लेबल, चेतावनियां)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in drugs that increase central… (रासाजिलिन लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (रैमेल्टियॉन लेबल, चेतावनियां और सावधानियां)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction of, withdrawal of, or changes in, dopaminergic therapy. (रोपिनिरोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (लिथियम लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

CNS Depressant Effects and Daytime Impairment: Impairs alertness and motor coordination including morning impairment. (लेम्बोरेक्सेंट लेबल, चेतावनियां और सावधानियां)

Withdrawal-Emergent Hyperpyrexia and Confusion A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. (लेवोडोपा लेबल, चेतावनियां और सावधानियां)

…others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval (e.g., pentamidine,… (लोपेरामाइड लेबल, चेतावनियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. (ल्यूरासिडोन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Withdrawal Emergent Hyperpyrexia and Confusion Although not reported with ZELAPAR in the clinical development program, a symptom complex resembling the neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with… (सेलेजिलिन लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

An increased risk cannot be excluded for haloperidol decanoate, other antipsychotics, or other patient populations. (हेलोपेरिडोल लेबल, चेतावनियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Some cases presented with features resembling neuroleptic malignant syndrome. (एटोमोक्सेटिन लेबल, दवाओं के इंटरैक्शन)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron hydrochloride injection has been safely administered with drugs representing benzodiazepines, neuroleptics and anti-ulcer medications commonly prescribed with antiemetic treatments. (ग्रैनिसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (टियागाबिन लेबल, चेतावनियां)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (डॉक्साप्राम लेबल, चेतावनियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (रेगुलर इंसुलिन (ह्यूमन) लेबल, दवाओं के इंटरैक्शन)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Seizures Like other antipsychotic drugs, REXULTI may cause seizures. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression. (ब्रेक्सपिप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Drugs Having No Clinically Important Interactions with REXULTI Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Drugs Having No Clinically Important Interactions with REXULTI Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)